The Quantellect read.As of Nov 19, 2026, 5 active firms cover TG Therapeutics Inc: 3 rate it Buy or better, 1 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $20.00 to $86.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $59.00 sits 11% below the current $66.12. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.60 next quarter toward $2.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Neutral
Strong Buy00%
Buy360%
Neutral120%
Sell120%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$59.00
-10.8% downside
Average target across 5 active firms as of Nov 19, 2026 vs $66.12 current
Highest Target$86.00
Average Target$59.00
Lowest Target$20.00
Detailed analyst forecasts for TGTX
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 3 of 5 active firms rate TGTX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TGTX EPS & revenue forecast
EPS · NEXT QUARTER
$0.60
Range $0.60 – $0.60 · 1 analysts · +235% YoY
Next period, 1 analysts expect TG Therapeutics Inc to earn $0.60 a share (range $0.60 – $0.60), versus $0.18 a year earlier. Full-year consensus is $0.97, growing to $2.55 the year after.
REVENUE · NEXT QUARTER
$298.0M
Range $283.0M – $314.4M · 1 analysts · +45% YoY
Revenue is expected to reach $298.0M (range $283.0M – $314.4M), +45.4% year-over-year. Full-year consensus is $999.3M, rising to $1.3B next year.
Top analysts covering TG Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TGTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$55.00-16.8% to target
Overall win rate
49%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Buy
$72.00+8.9% to target
Overall win rate
51%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$83.00+25.5% to target
Overall win rate
43%
+ Follow
#4
EW
Edward White
HC Wainwright & Co. · Rank #376
Buy
$55.00-16.8% to target
Overall win rate
31%
+ Follow
#5
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$78.00+18.0% to target
Overall win rate
24%
+ Follow
TGTX stock forecast FAQ
What is TGTX's average 12-month price target?+
The 5 active firms with a live target average $59.00 for TG Therapeutics Inc over the next 12 months, ranging from a $86.00 high to a $20.00 low, as of Nov 19, 2026.
Is TGTX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 5 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TGTX?+
The Street-high target is $86.00 (B. Riley Securities), and the Street-low is $20.00 (B of A Securities). The average of all 5 active-firm targets is $59.00.
How many active Wall Street firms cover TGTX?+
5 active firms have a recognized rating on TG Therapeutics Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TGTX?+
Among analysts who currently cover TGTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $55.00 target.
What is TG Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.60 per share (range $0.60 – $0.60) across 1 analysts. Full-year EPS is projected at $0.97, rising to $2.55 the following year.
How much revenue is TG Therapeutics Inc expected to report next quarter?+
Consensus revenue is $298.0M (range $283.0M – $314.4M). Full-year revenue is projected at $999.3M, growing to $1.3B next year.
Have analysts been upgrading or downgrading TGTX lately?+
As of Nov 19, 2026, 3 of 5 active firms rate TGTX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TGTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.